GSK to fully control JV from 1 June
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
GlaxoSmithKline (GSK) is expecting to complete its acquisition of Novartis’ 36.5% stake in the firms’ consumer healthcare joint venture on 1 June, according to the UK-based pharmaceuticals giant’s chief executive Emma Walmsley.